Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Myokarditis og/eller pericarditis efter mRNA COVID-19 VACCination National Surveillance Study (MYCOVACC)

2. november 2026 opdateret af: Cardiology Research UBC

Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection.

The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.

Studieoversigt

Undersøgelsestype

Observationel

Tilmelding (Anslået)

500

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Rekruttering
        • Vancouver General Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Nathaniel Hawkins, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients who have suffered or are suffering from 1) COVID-19 infection associated myocarditis, 2) COVID-19 infection associated pericarditis, 3) COVID-19 vaccine associated myocarditis, 4) COVID-19 vaccine associated pericarditis, 5) Alternative etiology myocarditis, 6) Alternative etiology pericarditis

Definition of myocarditis and pericarditis follows standard clinical definition as outlined in "Brighton Collaboration myocarditis case definition and levels of diagnostic certainty 1,2 and 3"

Beskrivelse

Inclusion Criteria:

  • Inclusion criteria for vaccine associated myocarditis/pericarditis.

    1. COVID-19 vaccination within previous 42 days. AND

    2. At least one cardiac symptom of suspected myocarditis/pericarditis (Appendix 5).

      OR At least two non-specific symptoms (Appendix 5). OR In infants and young children, at least two non-specific pediatric symptoms (Appendix 5).

      OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI).

      AND

    3. At least one of the following objective findings (Brighton Criteria case definitions, Appendices 1 to 5):

      1. Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation.
      2. Elevated myocardial biomarker (Troponin T, Troponin I, or CK-MB).
      3. Cardiac MRI abnormality.
      4. Echocardiographic abnormality.
      5. New or worsening arrhythmia on electrocardiogram, Holter monitor, or telemetry.
      6. Elevated inflammation biomarkers: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hs-CRP, or D-Dimer.
      7. Physical examination pericardial friction rub or pulsus paradoxus.
      8. Pericardial fluid or inflammation by imaging (echo, MRI, or CT).
      9. Enlarged heart on chest radiograph.

      AND

    4. No alternative cause of presentation. e.g. infectious or autoimmune myocarditis.

  • Inclusion criteria for COVID-19 associated myocarditis/pericarditis

    1. COVID-19 infection within the previous 42 days.

      AND

    2. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.

      AND

    3. No alternative cause of presentation.

Inclusion criteria alternative etiology myocarditis.

  1. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.

    AND

  2. No alternative cause of presentation.

Exclusion Criteria:

  • For prospective invitation and follow-up, inability to provide informed consent. Consent will be sought from patients or their authorised substitute decision maker.
  • Patients not fulfilling Brighton Criteria levels 1-3 will be excluded if they are level 4 (insufficient evidence for myocarditis) or Level 5 (not myocarditis) or have an alternative diagnosis such as myocardial infarction.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
mRNA COVID-19 vaccine associated myocarditis

Participants who had developed myocarditis within 42 days of getting a mRNA COVID-19 vaccine

Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

mRNA COVID-19 vaccine associated pericarditis

Participants who had developed pericarditis within 42 days of getting a mRNA COVID-19 vaccine

Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

COVID-19 infection associated myocarditis

Participants who had developed myocarditis within 42 days of being infected with the SARS-COV-2 virus

Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

COVID-19 infection associated pericarditis

Participants who had developed pericarditis within 42 days of being infected with the SARS-COV-2 virus

Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

Alternative etiology myocarditis

Any participants with myocarditis that is not associated with the mRNA COVID-19 vaccine or SARS-COV-2 viral infection

Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite Major Adverse Cardiac Event (MACE) at 30 days post vaccination (preferred by cardiovascular community) and at 42 days post vaccination (preferred by vaccine monitoring investigators)
Tidsramme: From date of vaccination and up to 3 years

Including any of:

  • Death from any cause.
  • Ventricular arrhythmia (ventricular fibrillation or ventricular tachycardia).
  • Heart block (type II or type III block).
  • Heart failure (national guideline criteria).
  • Left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] <55%).
  • Cardiac tamponade.
From date of vaccination and up to 3 years
Recovery of cardiac function in patients with previously documented abnormal cardiac function
Tidsramme: Through study completion, an average of 3 years

Patients with Left Ventricular Ejection Fraction (LVEF)<55% during anytime at baseline, with LVEF increase by 5% from worst baseline measurement

Through study completion, an average of 3 years
Quality of life using validated instruments at baseline, 3 months, 12 months, and annually
Tidsramme: Through study completion, an average of 3 years

Quality of life: EQ-5D-5L questionnaire for adults or EQ-5D-Y questionnaire for children.

Through study completion, an average of 3 years
Depression and anxiety using validated instruments at baseline, 3 months, 12 months, and annually
Tidsramme: Through study completion, an average of 3 years

Depression and anxiety data: PHQ-9 and GAD-7.

Through study completion, an average of 3 years
Physical activity using validated instruments at baseline, 3 months, 12 months, and annually
Tidsramme: Through study completion, an average of 3 years

Physical activity: International Activity Questionnaire.

Through study completion, an average of 3 years

Sekundære resultatmål

Resultatmål
Tidsramme
Individuelle komponenter af primært sammensat endepunkt 30 dage og 42 dage efter mRNA COVID-19 vaccination?
Tidsramme: Fra vaccinationsdatoen i op til tre år
Fra vaccinationsdatoen i op til tre år
Hyppighed af atrielle arytmier efter mRNA COVID-19-vaccination?
Tidsramme: Fra vaccinationsdatoen i op til tre år
Fra vaccinationsdatoen i op til tre år
Hyppighed af alle årsager og kardiovaskulær dødelighed efter mRNA COVID-19-vaccination?
Tidsramme: Fra vaccinationsdatoen i op til tre år
Fra vaccinationsdatoen i op til tre år
Hyppighed af alle årsager og kardiovaskulær indlæggelse efter mRNA COVID-19-vaccination?
Tidsramme: Fra vaccinationsdatoen i op til tre år
Fra vaccinationsdatoen i op til tre år
Hyppighed for tilbagefald af myocarditis/pericarditis efter mRNA COVID-19 vaccination?
Tidsramme: Fra vaccinationsdatoen i op til tre år
Fra vaccinationsdatoen i op til tre år
Hyppighed af constrictive pericarditis efter mRNA COVID-19 vaccination?
Tidsramme: Fra vaccinationsdatoen i op til tre år
Fra vaccinationsdatoen i op til tre år

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Nathaniel Hawkins, MD, Vancouver General Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. april 2023

Primær færdiggørelse (Anslået)

23. marts 2027

Studieafslutning (Anslået)

23. april 2027

Datoer for studieregistrering

Først indsendt

29. maj 2023

Først indsendt, der opfyldte QC-kriterier

24. oktober 2023

Først opslået (Faktiske)

26. oktober 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner